{"nctId":"NCT03344458","briefTitle":"A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial","startDateStruct":{"date":"2017-12-19","type":"ACTUAL"},"conditions":["Growth Hormone Deficiency, Pediatric","Endocrine System Diseases","Hormone Deficiency","Pituitary Diseases"],"count":298,"armGroups":[{"label":"TransCon hGH","type":"EXPERIMENTAL","interventionNames":["Drug: TransCon hGH"]}],"interventions":[{"name":"TransCon hGH","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Children who have completed a prior phase 3 TransCon hGH trial\n2. Children who have not permanently discontinued study drug in the prior trial\n3. Written, signed, informed consent of the parent or legal guardian of the subject and written assent of the subject as required by the IRB/HREC/IEC\n\nExclusion Criteria:\n\n1. Poorly-controlled diabetes mellitus (HbA1c â‰¥ 8.0%) or diabetic complications\n2. Evidence of closed epiphyses, defined as bone age \\> 14.0 years for females or \\> 16.0 years for males\n3. Major medical conditions unless approved by Medical Expert\n4. Known hypersensitivity to the components of the trial medication\n5. Likely to be non-compliant with respect to trial conduct (in regards to the subject and/or the parent/legal guardian/caregiver)\n6. Pregnancy\n7. Any other reason that in the opinion of the investigator would prevent the subject from completing participation or following the trial schedule","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Treatment-Emergent Adverse Events [Long-Term Safety and Tolerability]","description":"Long-term safety and tolerability of weekly lonapegsomatropin (TransCon hGH) treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Height Velocity by Visit","description":"Annualized height velocity (AHV) by visit with long-term dosing of weekly lonapegsomatropin treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.904","spread":"2.795"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.560","spread":"1.801"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.854","spread":"1.953"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.081","spread":"1.838"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.462","spread":"1.868"}]}]}]},{"type":"SECONDARY","title":"IGF-1 SDS by Visit","description":"Insulin-like Growth Factor-1 (IGF-1) standard deviation score (SDS) by visit with long-term dosing of weekly lonapegsomatropin treatment at Week 13, Week 52, Week 104, Week 156, and Week 208. IGF-1 SDS is the number of standard deviations above or below the mean IGF-1 level for a child of the same age and sex. The target range for IGF-1 SDS was 0 to +2. An IGF-1 SDS of 0 represents the population mean. If the IGF-1 SDS is \\< 0, then the negative score indicates an IGF-1 below the mean IGF-1 for a child of the same age and sex. If the IGF-1 SDS is \\> 0, then the positive score indicates an IGF-1 above the mean IGF-1 for a child of the same age and sex. A positive score of IGF-1 SDS indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.210","spread":"1.400"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.355","spread":"1.231"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.613","spread":"1.189"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.453","spread":"1.125"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.597","spread":"1.177"}]}]}]},{"type":"SECONDARY","title":"Height SDS - Change From Baseline","description":"Change in Height Standard Deviation Score (SDS) from baseline with long-term dosing of weekly lonapegsomatropin treatment at Week 13, Week 52, Week 104, Week 156, and Week 208. Height SDS is the number of standard deviations above or below the mean height for age and sex. A Standard Deviation Score of 0 equals the population mean. If the Height SDS is \\< 0, then the negative score indicates a height below the mean height for a child of the same age and sex. If the Height SDS is \\> 0, then the positive score indicates a height above the mean height for a child of the same age and sex. A positive change from baseline in Height SDS indicates improved outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.141","spread":"0.125"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.491","spread":"0.307"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.841","spread":"0.487"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.089","spread":"0.534"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.242","spread":"0.652"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":298},"commonTop":["Upper respiratory tract infection","COVID-19","Nasopharyngitis","Pyrexia","Headache"]}}}